Digestive Diseases and Sciences

, Volume 56, Issue 11, pp 3288–3295 | Cite as

Effect of Red Pepper on Symptoms of Irritable Bowel Syndrome: Preliminary Study

  • M. BortolottiEmail author
  • S. Porta
Original Article



Abdominal pain, that characterizes irritable bowel syndrome (IBS) together with bloating and disordered defecation, is mainly related to a visceral hypersensitivity due to an increase of TRPV1 nociceptive nerve fiber activity.


As capsaicin contained in red pepper is able to desensitize the TRPV1 fibres, we evaluated whether the red pepper oral administration can decrease the symptoms of visceral hypersensitivity in IBS patients.


The study was performed on 50 patients with IBS diagnosed following Rome II criteria. After a 2-week washout period, 23 patients were planned to receive 4 pills/day, for 6 weeks randomly and in a double blind manner, each containing 150 mg of red pepper powder with a coat that dissolves in the colon, and 27 patients placebo. The patients scored each day in a diary the abdominal pain and bloating intensities following the 5-point Likert scale. The weekly symptom mean scores and the final patient subjective evaluation on treatment effectiveness were statistically compared among groups and intra-groups with appropriate tests.


Eight patients dropped from the study: 6 in the red pepper group for abdominal pain and 2 in the placebo group. In 8 patients, the pills were reduced to 2/day, because of the abdominal pain at the onset of treatment. The intra-group comparisons showed that in patients taking red pepper the abdominal pain and bloating mean score values of the last weeks of treatment were significantly improved with respect to pre-treatment values, unlike patients taking placebo. The final patient subjective evaluation on the treatment effectiveness showed that red pepper group scored significantly better than placebo.


The results of this preliminary study indicate that the chronic administration of red pepper powder in IBS patients with enteric-coated pills was significantly more effective than placebo in decreasing the intensity of abdominal pain and bloating and was considered by the patients more effective than placebo.


Abdominal pain Capsaicin Irritable bowel syndrome Red pepper Visceral hypersensitivity 


Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol. 2010;25:691–699.PubMedCrossRefGoogle Scholar
  2. 2.
    Talley NJ, Zinsmeister AR, Van Dyke C, et al. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology. 1991;101:927–934.PubMedGoogle Scholar
  3. 3.
    Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ. 1992;304:87–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108–2131.PubMedCrossRefGoogle Scholar
  5. 5.
    Whitehead WE, Burnett CK, Cook EW III, et al. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 1996;41:2240–2253.CrossRefGoogle Scholar
  6. 6.
    Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45:1143–1147.Google Scholar
  7. 7.
    Sandler RS, Drossman DA, Nathan HP, et al. Symptom complaints and health care seeking behaviour in subjects with bowel dysfunction. Gastroenterology. 1984;87:314–318.PubMedGoogle Scholar
  8. 8.
    Spiegel BM, Grainek IM, Bolus R, et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med. 2004;164:1773–1780.PubMedCrossRefGoogle Scholar
  9. 9.
    Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut. 2002;51:167–171.CrossRefGoogle Scholar
  10. 10.
    Lembo NaliboffB, Munakata J, et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol. 1999;94:1320–1326.PubMedCrossRefGoogle Scholar
  11. 11.
    Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 1995;109:40–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Baron R. Neuropathic pain: a clinical prospective. Handb Exp Pharmacol. 2009;194:3–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology. 2003;124:1662–1671.PubMedCrossRefGoogle Scholar
  14. 14.
    Gwee KA, Graham C, McKendick MW, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999;44:400–406.PubMedCrossRefGoogle Scholar
  15. 15.
    Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122:1778–1783.PubMedCrossRefGoogle Scholar
  16. 16.
    Hasler WI. Visceral analgesia: an emerging concept for managing functional gastrointestinal disease. Gastroenterology. 1998;115:1023–1029.PubMedCrossRefGoogle Scholar
  17. 17.
    Holzer P, Holzer-Petche U. Pharmacology of inflammatory pain: local alteration in receptors and mediators. Dig Dis. 2009;27:24–30.PubMedCrossRefGoogle Scholar
  18. 18.
    Manthy PW, Hunt SP. Hot pepper and pain. Neuron. 1998;21:644–645.Google Scholar
  19. 19.
    Buck HS, Burks TF. The neuropharmacology of capsaicin: review of some recent observations. Pharmacol Rev. 1986;38:179–226.PubMedGoogle Scholar
  20. 20.
    Gunthorpe MJ, Szallasi A. Peripheral TRPV1 receptors as targets for drug development: new molecule and mechanisms. Curr Pharm Des. 2008;14:32–41.PubMedCrossRefGoogle Scholar
  21. 21.
    Lynn B. Capsaicin: actions on nociceptive C-fibres and therapeutic potential. Pain. 1990;41:61–69.PubMedCrossRefGoogle Scholar
  22. 22.
    Holzer P. Capsaicin: cellular targets, mechanism of action, and selectivity for thin sensory neurons. Pharmacol Rev. 1991;43:143–201.PubMedGoogle Scholar
  23. 23.
    Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology. 1994;107:271–293.PubMedGoogle Scholar
  24. 24.
    Christianson JA, Mcllwrath SL, Koeber HR, et al. Transient receptor potential vaniloid 1-immunopositive neurons in the mouse are more prevalent within colon afferent compared to skin and muscle afferent. Neurosciences. 2006;140:247–257.CrossRefGoogle Scholar
  25. 25.
    Jones RCW III, Xu L, Gebhart GF. The mechanosensitivity of mouse colon afferent fibres and their sensitization by inflammatory mediators require transient receptor potential vanilioid 1 and acid-sensing ion channel 3. Neurosciences. 2005;25:10981–10989.Google Scholar
  26. 26.
    Watson CP, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 1993;15:510–525.PubMedGoogle Scholar
  27. 27.
    Epstein JB, Marcoe JH. Topical application of capsaicin for treatment of oral neuropathic pain and trigeminal neuralgia. Oral Surg Oral Med Oral Pathol. 1994;77:135–140.PubMedCrossRefGoogle Scholar
  28. 28.
    Sicuteri F, BM FuscoB, Marabini S, et al. Beneficial effect of capsaicin application to the nasal mucosa in cluster headache. Clin J Pain. 1989;5:49–53.PubMedCrossRefGoogle Scholar
  29. 29.
    The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med. 1991;151:2225–2229.CrossRefGoogle Scholar
  30. 30.
    Barbanti G, Maggi CA, Beneforti P, et al. Relief of pain following intravescical capsaicin in patients with hypersensitive disorders of the lower urinary tract. Br J Urol. 1993;71:686–691.PubMedCrossRefGoogle Scholar
  31. 31.
    Rodriguez-Stanley S, Collings KL, Robinson M, et al. The effects of capsaicin on reflux, gastric emptying and dyspepsia. Aliment Pharmacol Ther. 2000;14:129–134.PubMedCrossRefGoogle Scholar
  32. 32.
    Bortolotti M, Coccia G, Grossi G. Red pepper and functional dyspepsia. N Eng J Med. 2002;346:947–948.CrossRefGoogle Scholar
  33. 33.
    Quigley EM. From coming relief to real understanding; how intestinal gas causes symptoms. Gut. 2003;52:1659–1661.PubMedCrossRefGoogle Scholar
  34. 34.
    Lee KJ, Kim JH, Cho SW. Relationship of underlying abnormalities in rectal sensitivity and compliance to distension with symptoms in irritable bowel syndrome. Digestion. 2006;73:133–141.PubMedCrossRefGoogle Scholar
  35. 35.
    Szallasi A, Nilsson S, Farkas-Szallasi T, et al. Vanilloid (capsaicin) receptors in the rat: distribution in the brain, regional differences in the spinal cord, axonal transport to the periphery, and depletion by systemic vanilloid treatment. Brain Res. 1995;703:175–183.PubMedCrossRefGoogle Scholar
  36. 36.
    Gonlachanvit S, Mahayosnond A, Kullavanijaya P. Effect of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceral nociception hypersensitivity. Neurogastroenterol Motil. 2009;21:23–32.PubMedCrossRefGoogle Scholar
  37. 37.
    Barbara G, De Giorgio R, Stanghellini V, et al. A role for inflammation in irritable bowel syndrome. Gut. 2002;51:141–144.CrossRefGoogle Scholar
  38. 38.
    Akbar A, Yiangou FacerP, et al. Increased capsaicin receptors TRV1-expressing sensory fibres in irritable bowel syndrome e and their correlation with abdominal pain. Gut. 2008;57:923–929.PubMedCrossRefGoogle Scholar
  39. 39.
    Szallasi A, Blumberg PM. Vaniloid (Capsaicin) receptors and mechanisms. Pharmacol Rev. 1999;51:159–212.PubMedGoogle Scholar
  40. 40.
    Yiangon Y, Facer P, Dyer NH, et al. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet. 2001;35:1338–1339.CrossRefGoogle Scholar
  41. 41.
    Kreis ME, Haupt W, Kirkup AJ, et al. Histamine sensitivity of mesenteric afferent nerves in the rat jejunum. Am J Physiol. 1998;275:G675–G680.PubMedGoogle Scholar
  42. 42.
    Kirkup AJ, Jiang W, Bunnet NW, et al. Stimulation of proteinase-activated receptor 2 excites jejunal afferent nerves in anaesthetised rats. J Physiol. 2003;552:89–601.CrossRefGoogle Scholar
  43. 43.
    Premkumar LS, Ahem GP. Induction of vaniloid receptor channel activity by protein kinase C. Nature. 2000;408:985–990.PubMedCrossRefGoogle Scholar
  44. 44.
    Sugiuar T. Bielefeldt k, Gebhart GF. TRPV1 function in mouse colon sensory neurons is enhanced by metabotropic 5-hydroxythryptamine receptor activation. J Neurosci. 2004;24:9521–9530.PubMedCrossRefGoogle Scholar
  45. 45.
    Barbara G, Wang B, Stanghellini V, et al. Mast cell dependent excitation of visceral nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26–37.PubMedCrossRefGoogle Scholar
  46. 46.
    Stead RH, Dixon MF, Bramwell NH, et al. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology. 1989;97:575–585.PubMedGoogle Scholar
  47. 47.
    Jones RCW III, Otsuka E, Vagstrom E, et al. Short-term sensitization of colon mechanoreceptors is associated with long-term hypersensitivity to colon distension in the mouse. Gastroenterology. 2007;133:184–194.PubMedCrossRefGoogle Scholar
  48. 48.
    Kimbal ES, Fallace NH, Schneider CR, et al. Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium induced colitis in mice. Neurogastroenterol Motil. 2004;15:811–818.CrossRefGoogle Scholar
  49. 49.
    Kihara N, de la Fuente SG, Fujino K, et al. Vanilloid receptor 1 containing primary sensory neurones mediate dextran sulphate sodium induced colitis in rats. Gut. 2003;52:713–719.PubMedCrossRefGoogle Scholar
  50. 50.
    Vinston J, Shenoy M, Medly D, et al. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastreoenterology. 2007;132:615–627.CrossRefGoogle Scholar
  51. 51.
    Cavagnaro J, Lewis RM. Bidirectional regulatory circuit between the immune and neuroendocrine system. Year Immunol. 1989;4:241–252.PubMedGoogle Scholar
  52. 52.
    Mori N, Suzuki R, Furuno T, et al. Nerve-mast cell (RBL) interaction: RBL membrane ruffling occurs at the contact site with an activated neurite. Am J Physiol Cell Physiol. 2002;283:C1738–C1744.PubMedGoogle Scholar
  53. 53.
    Shanahan F, Denburg JA, Fiox J, et al. Mast cell heterogeneity: effects of neuroenteric peptides on histamine release. J Immunol. 1985;135:1331–1337.PubMedGoogle Scholar
  54. 54.
    Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.PubMedCrossRefGoogle Scholar
  55. 55.
    Geppetti P, Capone JG, Trevisani M, et al. CGRP and migraine: neurogenic inflammation revisited. J Headache Pain. 2005;6:61–70.PubMedCrossRefGoogle Scholar
  56. 56.
    Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest. 2007;117:636–647.PubMedCrossRefGoogle Scholar
  57. 57.
    Klooker TK, Kuiken SD, Lei A, et al. Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome. Aliment Pharmacol Ther. 2007;15(26):605–615.CrossRefGoogle Scholar
  58. 58.
    Macsharry J, O’Mahony L, Fanning A, et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol. 2008;43:1467–1476.PubMedCrossRefGoogle Scholar
  59. 59.
    Barbara G, Stanghellini V, Cremon C, et al. Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome. Dig Dis. 2009;27:115–121.PubMedCrossRefGoogle Scholar
  60. 60.
    Kissin I, Bright CA, Bradley EL Jr. Selective and long-standing neural blockade with resiniferatoxin prevents inflammatory pain hypersensitivity. Anaesth Analog. 2002;94:1253–1258.CrossRefGoogle Scholar
  61. 61.
    Szallasi A, Cruz F, Geppetti P. TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol Med. 2006;12:545–554.PubMedCrossRefGoogle Scholar
  62. 62.
    Holzer P. TRPV1 and the gut from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. Eur J Pharmacol. 2004;500:231–241.PubMedCrossRefGoogle Scholar
  63. 63.
    Bandell M, Macpherson LJ, Patapuotian A. From chills to chilis: mechanisms for thermosensation and chemesthesis via thermo TRPs. Curr Opin Neurobiol. 2007;17:490–497.PubMedCrossRefGoogle Scholar
  64. 64.
    Boesmans W, Owsianik G, Tack J, et al. TRP channels in neurogastroenterology: opportunities for therapeutic intervention. Br J Pharmacol. 2011;162:18–37.PubMedCrossRefGoogle Scholar
  65. 65.
    Gwee KA, Lu CL, Ghoshal UC. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J Gastroenterol Hepatol. 2009;24:1601–1607.PubMedCrossRefGoogle Scholar
  66. 66.
    Perveen I, Hasan M, Masud MA, et al. Irritable bowel syndrome in a Bangladeshi urban community: prevalence and health care seeking pattern. Saudi J Gastreonterol. 2009;15:239–243.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Internal Medicine and GastroenterologyUniversity of BolognaBolognaItaly
  2. 2.Medical DepartmentSOFARMilanItaly

Personalised recommendations